SAP Doubles Down, Commits Another $1B to Sapphire Ventures

Silicon Valley venture capital firm Sapphire Ventures, whose ancestry traces back to the former corporate venture investing arm of German software giant SAP, said today it has secured $1 billion in capital from SAP.

That adds up to $2.4 billion in assets under management for Palo Alto, CA-based Sapphire—-all pledged by SAP SE (NYSE: [[ticker:SAP]]), its only investor (limited partner) so far.

“I’m not sure how many other institutions have committed so much to a single fund,” says Sapphire CEO and managing director Nino Marakovic. “Maybe Google (to Google Ventures.)”

In 2010 and 2011, Marakovic shepherded the spinoff of SAP’s former in-house venture arm, SAP Ventures, into the new independent venture capital firm later renamed as Sapphire Ventures. The firm has grown from 7 or eight staffers to its current 27, of whom about half are investment professionals, he says. Taken together, the two venture outfits invested in more than 135 companies. Sapphire alone has backed about 45.

Business writers have remarked on how little press coverage Sapphire has drummed up compared to other VC firms making similar investments. But on the occasion of this large fundraising round, the firm took a little license to reach out to reporters and crow a bit.

“This is the seventh largest fundraise this year,” Marakovic says. The big haul puts Sapphire in the same company with Andreessen Horowitz, Kleiner Perkins Caufield & Byers, Norwest Venture Partners, and other heavy hitters.

Four of Sapphire’s portfolio companies went public in 2015—Apigee, Box, Fitbit and Square. They followed three in 2014—-Five9, Imprivata, and OnDeck. Citing an article by PitchBook, Sapphire says it placed among the top venture firm investors that had backed U.S. tech companies that managed to pull off an IPO since 2011. Sapphire was behind Sequoia Capital, IVP, Accel Partners, and New Enterprise Associates. It tied with DAG Ventures for fifth place.

Sapphire doesn’t comment on its financial performance.

Marakovic says Sapphire’s close affiliation with SAP brings benefits to the venture firm’s portfolio companies as well as to the big enterprise software company. Sapphire taps the SAP networks to introduce young companies to customers and showcase them at events. The venture firm, in turn, is a conduit of global information about early innovation trends in tech sectors for the big German company, he says.

“They see us as a sensor network,” Marakovic says.

Sapphire invests directly in growth-stage technology startups, but it also invests as a limited partner in the funds of other VCs, who support early stage companies. Sapphire helps and monitors the progress of those very young startups, making it well-positioned to lead or participate in follow-on financing rounds for promising ones, Marakovic says.

Sapphire is free to seek investments from limited partners other than SAP, “but SAP is a great partner for us,” Marakovic says. At least at this point, “we saw no reason to rock the boat,” he says.

Sapphire has raised money in stages, beginning with an initial $353 million for its first direct investment fund, and $150 million for investments in other venture capital firms. SAP later pitched in another $651 million for direct investing in startups, and $250 million more to support other venture funds.

From the bulk of its new $1 billion, Sapphire is now creating its third direct investment fund with an amount exceeding $651 million, Marakovic says. It will use the remainder to

Author: Bernadette Tansey

Bernadette Tansey is a former editor of Xconomy San Francisco. She has covered information technology, biotechnology, business, law, environment, and government as a Bay area journalist. She has written about edtech, mobile apps, social media startups, and life sciences companies for Xconomy, and tracked the adoption of Web tools by small businesses for CNBC. She was a biotechnology reporter for the business section of the San Francisco Chronicle, where she also wrote about software developers and early commercial companies in nanotechnology and synthetic biology.